<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autoinflammatory diseases mediated by inflammasomes and related IL-1 family cytokines (inflammasomopathies)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autoinflammatory diseases mediated by inflammasomes and related IL-1 family cytokines (inflammasomopathies)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autoinflammatory diseases mediated by inflammasomes and related IL-1 family cytokines (inflammasomopathies)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A Nigrovic, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Sundel, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1820149568"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Autoinflammatory diseases are conditions of pathogenic chronic or recurrent inflammation mediated by antigen-independent activation of the immune system. A broad spectrum of autoinflammatory diseases is now recognized, differing markedly from one another in pathogenesis and clinical manifestations. This topic covers autoinflammatory diseases that originate in aberrant activation of the inflammasome, sometimes termed "the inflammasomopathies." A general discussion of autoinflammatory diseases is available separately. (See  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a>.)</p><p>Additional topics cover other specific autoinflammatory diseases:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2634.html" rel="external">"Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever"</a> and  <a class="medical medical_review" href="/d/html/2574.html" rel="external">"Management of familial Mediterranean fever"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5956.html" rel="external">"Hyperimmunoglobulin D syndrome: Pathophysiology"</a> and  <a class="medical medical_review" href="/d/html/5954.html" rel="external">"Hyperimmunoglobulin D syndrome: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5955.html" rel="external">"Hyperimmunoglobulin D syndrome: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5580.html" rel="external">"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/116307.html" rel="external">"Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/122508.html" rel="external">"Autoinflammatory diseases mediated by NFkB and/or aberrant TNF activity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/122509.html" rel="external">"Autoinflammatory diseases mediated by miscellaneous mechanisms"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/132472.html" rel="external">"Deficiency of adenosine deaminase 2 (DADA2)"</a>.)</p><p></p><p class="headingAnchor" id="H1727714331"><span class="h1">OVERVIEW OF THE INFLAMMASOME</span><span class="headingEndMark"> — </span>Inflammasomes are cytoplasmic protein complexes whose triggered assembly unleashes a set of highly proinflammatory consequences, including but not limited to activation and release of interleukin (IL) 1-beta and other proteins (<a class="graphic graphic_figure graphicRef128994" href="/d/graphic/128994.html" rel="external">figure 1</a>) [<a href="#rid1">1,2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Inflammasomes are activated by a range of pathogen-derived or environmental signals. Detection of these stimuli triggers formation of a large cytoplasmic multimolecular complex that serves to activate a protease that in turn activates effector molecules such as IL-1-beta. The result is release of IL-1-beta and IL-18 and sometimes a proinflammatory form of cell death termed pyroptosis [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The three major elements of an inflammasome are a scaffold protein that regulates its assembly; the protease caspase 1, also called IL-1-converting enzyme; and the linker/adaptor protein apoptosis-associated speck-like protein containing a C-terminal caspase-recruitment domain (ASC) that connects these molecules together, enabling molecules of caspase 1 to activate each other via proteolysis. Many ASC molecules form part of a single inflammasome, providing a large surface area for caspase 1 activation. A video model of inflammasome assembly is <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3D-FNFZ9F1eB4&amp;token=3BBziCZQDrEhIlt93szQloH6eZnp6PMXkxC7JnVMP%2FWLVka3fW6IH4BbDV9eqcGw74WKrsbBroq29bsZcgu5wQ%3D%3D&amp;TOPIC_ID=122506" target="_blank">available</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are at least six different inflammasomes that contain all three archetypal components, distinguished by the scaffold protein that regulates their assembly. These scaffold proteins are pyrin, cryopyrin (also called nucleotide-binding oligomerization domain-like receptor family, caspase recruitment domain-containing [NLRC] 3), NLRC4, nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing (NLRP) 1B, NLRP12, and absent in melanoma (AIM) 2. Each protein resides in an inactive form in the cytoplasm until exposed to specific triggers, whereupon conformational changes enable it to initiate inflammasome formation. A further inflammasome, called the noncanonical inflammasome, is triggered by intracellular bacterial lipopolysaccharide, recognized directly by caspases 4 and 5 without an intermediate scaffold protein [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upon activation, caspase 1 can remain associated with the inflammasome or diffuse away into the cytoplasm. Caspase 1 cleaves inactive pro-IL-1-beta into IL-1-beta. It also cleaves other IL-1 family cytokines, converting inert pro-IL-18 to active IL-18 and deactivating IL-33. Generation of IL-1-beta requires transcription of procytokine followed by processing through an active inflammasome, a two-step regulatory system that provides tight control of this potent proinflammatory mediator. By contrast, pro-IL-18 is expressed constitutively, with further production induced by inflammatory stimuli [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IL-1-beta and IL-18 lack signal sequences required for release through conventional mechanisms. Instead, the inflammasome enables their secretion by cleaving another protein termed gasdermin D [<a href="#rid5">5</a>]. Cleaved gasdermin D inserts into the cell membrane, forming pores that allow cytokine exit, selecting preferentially for mature IL-1-beta and IL-18 on the basis of charge [<a href="#rid6">6</a>]. Inflammasome activation may also enable release of IL-1-alpha [<a href="#rid7">7</a>]. These pores also disrupt transmembrane electrolyte gradients, potentially triggering a proinflammatory form of cell death termed <strong>pyroptosis</strong> that can entrap intracellular pathogens [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammasomes can be "shut off" by encapsulation in an intracellular vacuole, a process termed autophagy [<a href="#rid9">9</a>]. Intact inflammasomes can be released from cells, although the biologic importance of extracellular inflammasomes is unknown [<a href="#rid10">10,11</a>].</p><p></p><p class="headingAnchor" id="H2337491743"><span class="h1">DISEASES RELATED TO INFLAMMASOME ACTIVATION</span><span class="headingEndMark"> — </span>The inflammasome-mediated diseases can be grouped according to inflammasome affected (<a class="graphic graphic_table graphicRef130004" href="/d/graphic/130004.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H683010217"><span class="h2">The pyrin inflammasome</span><span class="headingEndMark"> — </span>The inflammasome scaffold protein pyrin is encoded by the gene MEFV innate immunity regulator, pyrin (<em>MEFV</em>), a name that reflects its discovery as the gene responsible for familial Mediterranean fever (FMF) [<a href="#rid12">12,13</a>]. Pyrin is normally maintained in an inactive state due to phosphorylation by the kinase Ras homolog gene family, member A (RhoA), a protein also involved in cell migration. Major human pathogens, including <em>Yersinia pestis</em> (the plague bacterium) and species of Clostridia, produce toxins that inactivate RhoA, thereby releasing pyrin from inhibition and triggering formation of the pyrin inflammasome [<a href="#rid2">2,14,15</a>]. Microtubules participate in normal pyrin inflammasome assembly, potentially helping to explain the therapeutic value of the microtubule inhibitor <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid16">16</a>]. Genetic defects affecting the pyrin inflammasome are implicated in several autoinflammatory diseases.</p><p class="headingAnchor" id="H271899789"><span class="h3">Familial Mediterranean fever</span><span class="headingEndMark"> — </span>FMF (MIM #249100) is the most common of the monogenic autoinflammatory syndromes. FMF arises from gain-of-function pathogenic variants in <em>MEFV</em>, resulting in accelerated formation of the pyrin inflammasome. Most patients with FMF have pathogenic variants in both alleles, but a substantial minority have only one pathogenic variant. Indeed, mice rendered deficient in pyrin remain largely well, while those rendered transgenic for an FMF-associated pyrin variant develop inflammatory disease [<a href="#rid17">17</a>]. Thus, it is the presence of hyperfunctional pyrin that is the cause of inflammation in FMF, reflecting escape from regulatory mechanisms that normally constrain assembly of the pyrin inflammasome [<a href="#rid2">2</a>]. Accordingly, although long held to be autosomal recessive, FMF is now commonly regarded as autosomal dominant with limited penetrance.</p><p>FMF is characterized by episodic attacks of fever lasting one to three days. Most patients also experience abdominal pain, pleurisy, and arthralgias or arthritis, the result of accompanying serositis and synovitis. Attacks are accompanied by an elevation in peripheral white blood cell count and acute-phase markers, while fluid from inflamed joints exhibits a neutrophil-predominant leukocytosis. Persistent inflammation can lead to secondary (amyloid A [AA]) amyloidosis.</p><p>The diagnosis may be strongly suggested by patient ethnicity. Sephardic Jews; Armenians; North Africans; Turks; and, to a lesser extent, Ashkenazi Jews, Greeks, and Italians are potential carriers. However, individuals outside of these groups have also been affected.</p><p>The pathophysiology, clinical manifestations, diagnosis, and management of FMF are discussed separately. (See  <a class="medical medical_review" href="/d/html/2634.html" rel="external">"Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever"</a> and  <a class="medical medical_review" href="/d/html/2574.html" rel="external">"Management of familial Mediterranean fever"</a>.)</p><p class="headingAnchor" id="H2129582423"><span class="h3">Pyrin-associated autoinflammation with neutrophilic dermatosis</span><span class="headingEndMark"> — </span>Pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND; MIM #608068) is caused by pathogenic variants in <em>MEFV</em> that disrupt its phosphorylation by RhoA, resulting in constitutive assembly of the pyrin inflammasome [<a href="#rid18">18,19</a>]. Cell activation that induces production of pro-IL-1-beta, for example by bacterial lipopolysaccharide, thereby becomes sufficient to trigger generation and release of the highly potent inflammatory mediator IL-1-beta. Despite the close pathophysiologic similarity to FMF, patients with PAAND may have prolonged episodes of fever lasting up to a few weeks and characteristically exhibit severe neutrophil skin inflammation, including cystic acne, hidradenitis suppurativa, and pyoderma gangrenosum, in addition to arthralgia/arthritis and myalgia/myositis. Like FMF, the familial pattern is autosomal dominant with limited penetrance. IL-1-beta antagonism may be effective, but some patients respond better to tumor necrosis factor (TNF) inhibition [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/5571.html" rel="external">"Neutrophilic dermatoses"</a>.)</p><p class="headingAnchor" id="H1138845437"><span class="h3">Hyperimmunoglobulin D syndrome</span><span class="headingEndMark"> — </span>Hyperimmunoglobulin D syndrome (HIDS; MIM #260920, mevalonate kinase deficiency) is an autosomal recessive periodic fever syndrome usually associated with pathogenic variants in the <em>MVK</em> gene that encodes mevalonate kinase, a key enzyme in the nonsterol isoprenoid biosynthesis pathway. These pathogenic variants reduce, but do not abolish, mevalonate kinase activity. This defect impairs phosphorylation of pyrin, resulting in inflammation mediated through the pyrin inflammasome [<a href="#rid20">20,21</a>].</p><p>More than two-thirds of patients with HIDS present within the first year of life with episodic attacks of fever lasting three to seven days, accompanied, in most cases, by chills, cervical lymphadenopathy, abdominal pain, and vomiting or diarrhea. Some patients experience headache, arthralgias or arthritis, aphthous ulceration, a pleomorphic rash, and, occasionally, splenomegaly. Attacks may be precipitated by vaccination, viral infection, trauma, and stress.</p><p>Most patients have characteristic abnormalities in immunoglobulins, including elevated levels of immunoglobulin D (IgD; &gt;100 international units/mL), and 80 percent also have elevated immunoglobulin A (IgA). Acute-phase reactants rise strikingly with fevers and sometimes remain elevated between episodes.</p><p>Pathogenic variants in <em>MVK</em> that abolish enzyme activity result in mevalonic aciduria (MIM #610377), an autosomal recessive disease characterized by developmental delay, hepatosplenomegaly, dysmorphic features, and failure to thrive in addition to episodic fevers.</p><p>The clinical manifestations, diagnosis, pathophysiology, and management of HIDS are discussed in detail elsewhere.<em> </em>(See  <a class="medical medical_review" href="/d/html/5954.html" rel="external">"Hyperimmunoglobulin D syndrome: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5956.html" rel="external">"Hyperimmunoglobulin D syndrome: Pathophysiology"</a> and  <a class="medical medical_review" href="/d/html/5955.html" rel="external">"Hyperimmunoglobulin D syndrome: Management"</a>.)</p><p class="headingAnchor" id="H1300344927"><span class="h3">PAPA syndrome</span><span class="headingEndMark"> — </span>The syndrome of pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA; MIM #174200) is a rare, autosomal dominant condition resulting from pathogenic variants affecting the gene <em>PSTPIP1</em>, encoding the protein proline/serine/threonine phosphatase-interacting protein 1 [<a href="#rid22">22</a>]. PAPA is considered a pyrin-related autoinflammatory disease because <em>PSTPIP1</em> and pyrin interact and because patients may respond to IL-1-beta blockade [<a href="#rid23">23-25</a>]. However, the mechanism by which <em>PSTPIP1</em> pathogenic variants alter pyrin function to trigger excess IL-1-beta production remain undefined.</p><p>PAPA presents in the first decade of life with oligoarticular, destructive arthritis, typically involving the elbow, knee, and/or ankle [<a href="#rid26">26</a>]. Severe cystic acne develops in most patients in early adolescence, while pyoderma gangrenosum and pathergy-like sterile abscesses at injection sites occur in a subset of patients. Bone marrow suppression in the event of exposure to sulfonamide medications may also be observed. Some patients may manifest PAPA together with hidradenitis suppurativa (PAPASH syndrome) [<a href="#rid27">27</a>]. Glucocorticoids can be employed for short-term disease control, and some patients exhibit excellent response to anti-TNF therapy [<a href="#rid28">28</a>]. Patients with PAPA demonstrated elevated local IL-1-beta production and aberrant neutrophil responses to this cytokine; correspondingly, response to IL-1 blockade has also been reported [<a href="#rid25">25,29</a>]. (See  <a class="medical medical_review" href="/d/html/13782.html" rel="external">"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/83623.html" rel="external">"Pyoderma gangrenosum: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris"</a>.)</p><p><em>PSTPIP1 </em>is implicated in a related autoinflammatory disease, <strong>hyperzincemia and hypercalprotectinemia</strong> (<strong>Hz/Hc</strong>; MIM %194470) [<a href="#rid30">30,31</a>]. Patients with this disease exhibit prominent systemic inflammation, with manifestations that may include skin inflammation, arthritis, lymphadenopathy, and cytopenias including neutropenia, anemia, and thrombocytopenia. Associated mutations in <em>PSTPIP1</em> are distinct from those in PAPA and further increase the affinity between <em>PSTPIP1</em> and pyrin. Compared with PAPA patients, persons with Hz/Hc exhibit markedly elevated concentration of S100 protein complex migration inhibitory factor-related protein (MRP) 8/14 and of zinc, which binds MRP8/14. Response to IL-1-beta blockade is observed but inconsistent [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H2622093721"><span class="h3">Periodic fever, immunodeficiency, and thrombocytopenia (PFIT)</span><span class="headingEndMark"> — </span>Patients with PFIT, which is caused by homozygous missense mutations in WD40 repeat domain 1 (WDR1), a protein involved in disassembly of the actin cytoskeleton [<a href="#rid32">32</a>], develop thrombocytopenia and a spontaneous autoinflammatory disease characterized by neutrophilic infiltration of multiple tissues [<a href="#rid33">33</a>]. Neutropenia and neutrophil dysfunction is also observed [<a href="#rid34">34</a>]. In mice bearing a hypomorphic mutation in the Wdr1 gene, the pyrin inflammasome interacts with the cytoskeleton, and inflammation in these animals is mediated largely through pyrin and the monocyte-derived IL-18, although not by IL-1-beta, a divergence that may reflect the different priming and activation signals governing generation of these mediators [<a href="#rid35">35</a>]. Two siblings with PFIT presented in the first weeks of life with recurrent systemic inflammation [<a href="#rid32">32</a>]. Fevers lasting three to seven days recurred every 6 to 12 weeks, with accompanying elevation in erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and circulating IL-18. Other features included oral ulcers with scarring, perianal ulcers, thrombocytopenia, and immunodeficiency with susceptibility to bacterial and fungal (<em>Pneumocystis jirovecii</em>) pathogens. Glucocorticoids, <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, and IL-1 blockade were of modest effect. One patient died, and the other recovered with allogenic hematopoietic cell transplantation.</p><p class="headingAnchor" id="H685095627"><span class="h3">NOCARH syndrome</span><span class="headingEndMark"> — </span>Patients with mutations in cell division cycle 42 (CDC42) can develop a syndrome characterized by <strong>N</strong>eonatal <strong>O</strong>nset of pan<strong>C</strong>ytopenia, <strong>A</strong>utoinflammation, <strong>R</strong>ash, and episodes of <strong>H</strong>emophagocytic lymphohistiocytosis (NOCARH) [<a href="#rid36">36</a>]. CDC42 is a GTPase that functions as an intermediary in multiple intracellular processes, including pyrin inflammasome assembly [<a href="#rid37">37</a>]. As a result of mutant protein mistrafficking, patient peripheral blood mononuclear cells produce abundant IL-1-beta and IL-18 [<a href="#rid36">36,37</a>]. Nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) overactivation is also reported [<a href="#rid38">38</a>]. Whereas IL-1 antagonists partially ameliorate the phenotype, recurrent hemophagocytic lymphohistiocytosis proved fatal except in a patient treated with interferon gamma blockade as a bridge to allogenic bone marrow transplantation, which appeared curative [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H3608758087"><span class="h2">The cryopyrin inflammasome</span><span class="headingEndMark"> — </span>Diseases resulting from pathogenic variants in the cryopyrin gene <em>NLRP3</em> were the first autoinflammatory diseases recognized to reflect aberrant inflammasome assembly. The cryopyrin scaffold protein is normally activated in response to triggers including adenosine triphosphate (ATP), bacterial and viral components, and crystals of uric acid, calcium pyrophosphate, and cholesterol [<a href="#rid2">2</a>]. Recognition that the cryopyrin inflammasome is also activated by crystals has led to recognition that the common diseases gout (monosodium urate crystals), pseudogout (calcium pyrophosphate dihydrate crystals), and even atherosclerotic cardiovascular disease (cholesterol crystals) could potentially be considered autoinflammatory.</p><p class="headingAnchor" id="H2190246717"><span class="h3">Cryopyrin-associated periodic syndromes</span><span class="headingEndMark"> — </span>Gain-of-function pathogenic variants in <em>NLRP3</em> result in a family of autosomal dominant syndromes termed the cryopyrin-associated periodic syndromes (CAPS), reflecting principally the overproduction of IL-1-beta. Patients with CAPS typically fall into one of three clinical syndromes with overlapping clinical features:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial cold autoinflammatory syndrome </strong>(FCAS1; MIM #120100), the mildest cryopyrinopathy, is manifested by brief (usually &lt;24 hours) episodes of fever and maculopapular or urticarial rashes triggered by exposure to cold, such as entering an air-conditioned building. Cold is also a trigger for inflammation in other autoinflammatory syndromes including FCAS2 (mutation in <em>NLRP12</em>) and FCAS3 (mutation in phospholipase C, gamma 2 [<em>PLCG2</em>], also called PLCG2-associated antibody deficiency and immune dysregulation [PLAID]) [<a href="#rid25">25,26</a>]. (See <a class="local">'The NLRP12 inflammasome'</a> below and  <a class="medical medical_review" href="/d/html/122509.html" rel="external">"Autoinflammatory diseases mediated by miscellaneous mechanisms", section on 'PLAID/APLAID'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muckle-Wells syndrome </strong>(MWS; MIM #191900) is associated with fevers and urticarial rashes that are not typically cold associated. Over time, some patients develop hearing loss and systemic amyloidosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal-onset multisystem inflammatory disorder </strong>(NOMID, also called chronic infantile neurologic cutaneous and articular syndrome [CINCA]; MIM #607115), the most severe cryopyrinopathy, is characterized by persistent fevers and rashes, essentially from birth, associated with chronic meningitis and cartilaginous/bony deformities.</p><p></p><p>The genetics, clinical manifestations, pathogenesis, prognosis, and treatment of CAPS are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a>.)</p><p class="headingAnchor" id="H4089937988"><span class="h3">Majeed syndrome</span><span class="headingEndMark"> — </span>Majeed syndrome (MIM #609628) is an autosomal recessive disease caused by biallelic mutations in the lipin 2 gene (LPIN2), which is involved in lipid metabolism [<a href="#rid39">39</a>]. Defects in <em>LPIN2</em> disrupt normal regulation of the NALP3 inflammasome, resulting in excess IL-1-beta production by mutant cells [<a href="#rid40">40</a>]. Features of Majeed syndrome include sterile osteolytic lesions, congenital dyserythropoietic anemia, and neutrophilic dermatosis [<a href="#rid41">41</a>]. Most patients present before the age of two years with additional features that include fever and marked elevation of inflammatory markers. Compared with patients with chronic nonbacterial osteomyelitis, patients typically present at a younger age and exhibit a more severe and prolonged course. Patients may respond to IL-1 blockade [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/118084.html" rel="external">"Chronic nonbacterial osteomyelitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO)"</a>.)</p><p class="headingAnchor" id="H4275412942"><span class="h2">The NLRC4 inflammasome</span><span class="headingEndMark"> — </span>Nucleotide-binding oligomerization domain-like receptor family, caspase recruitment domain-containing (NLRC) 4 is a scaffold protein that forms an inflammasome upon recognition of bacterial virulence factors such as flagellin. Gain-of-function pathogenic variants in <em>NLRC4</em> result in a condition termed <strong>autoinflammation with infantile enterocolitis (AIFEC)</strong>,<strong> </strong>characterized by systemic autoinflammation with recurrent fever, malaise, splenomegaly, vomiting, intermittent rash, and enterocolitis [<a href="#rid43">43,44</a>]. Additional hallmarks are episodes of macrophage activation syndrome (MAS) and extremely high levels of IL-18, even after clinical improvement with IL-1 blockade. The prevalence of enterocolitis in this condition mirrors the predominantly intestinal expression of NLRC4 in an animal model [<a href="#rid45">45</a>]. Improvement in NLRC4-mediated disease has been reported after IL-18 blockade [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Rheumatologic disorders/MAS'</a>.)</p><p class="headingAnchor" id="H32234542"><span class="h2">The NLRP1 inflammasome</span><span class="headingEndMark"> — </span>Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 1 (NLRP1) was the scaffold protein first noted to mediate inflammasome assembly [<a href="#rid1">1</a>]. Unlike the other scaffold proteins, NLRP1 appears to be activated via proteolysis, including by bacterial virulence factors such as anthrax lethal toxin [<a href="#rid2">2</a>]. NLRP1 is expressed primarily in keratinocytes, such that aberrant activation manifests mainly as skin disease, including <strong>multiple self-healing palmoplantar carcinoma (MSPC)</strong> and <strong>familial keratosis lichenoides chronica (FKLC)</strong> [<a href="#rid47">47</a>]. Several families with dyskeratosis and arthritis have also been described, a condition termed <strong>NLRP1-associated autoinflammation with arthritis and dyskeratosis (NAIAD)</strong> [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H859161377"><span class="h2">The NLRP12 inflammasome</span><span class="headingEndMark"> — </span>Pathogenic variants in nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 12 (NLRP12) result in FCAS2, a disease that presents similarly to FCAS resulting from mutations in <em>NLRP3</em> (the cryopyrin inflammasome) [<a href="#rid49">49</a>] (see <a class="local">'Cryopyrin-associated periodic syndromes'</a> above). Exposure to generalized cold results in fevers lasting between one and seven days, accompanied by elevation in circulating inflammatory markers, urticaria, arthralgia, and myalgias. Sensorineural hearing loss, optic neuritis, and amyloidosis reminiscent of the cryopyrinopathy spectrum have been reported. However, the phenotypic spectrum of NLRP12-associated diseases appears to be broad, with cold triggering reported in only 10 of 33 pediatric cases (30 percent); more common features were fevers (100 percent), polyarthralgia/arthritis (55 percent), abdominal pain/diarrhea (48 percent), and rash (45 percent, typically urticarial) [<a href="#rid50">50</a>]. NLRP12 also suppresses the noncanonical pathway activating the proinflammatory transcription factor complex NFkB, illustrating the tendency of autoinflammatory disorders to engage multiple proinflammatory pathways [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/122508.html" rel="external">"Autoinflammatory diseases mediated by NFkB and/or aberrant TNF activity"</a>.)</p><p class="headingAnchor" id="H592909194"><span class="h2">The AIM2 inflammasome</span><span class="headingEndMark"> — </span>The absent in melanoma 2 (AIM2) scaffold protein recognizes a broad range of pathogens, including double-stranded deoxyribonucleic acid (DNA) viruses [<a href="#rid2">2</a>]. Implicated in both immune defense and in the pathophysiology of cancer and psoriasis, no autoinflammatory disease mediated by pathogenic variants affecting AIM2 has yet been described.</p><p class="headingAnchor" id="H1918889768"><span class="h1">DISEASES RELATED TO OTHER IL-1 FAMILY PROTEINS</span><span class="headingEndMark"> — </span>The IL-1 family includes not only IL-1-beta and IL-18 but also the proinflammatory cytokine IL-36 and the antiinflammatory cytokine blocker IL-1 receptor antagonist (IL-1RA). Deficiency of IL-1RA (DIRA) or a related inhibitor of IL-36 also cause autoinflammatory disease.</p><p class="headingAnchor" id="H1960453114"><span class="h2">Deficiency of the IL-1 receptor antagonist (DIRA)</span><span class="headingEndMark"> — </span>DIRA (also called osteomyelitis, sterile multifocal, with periostitis and pustulosis [OMPP]; MIM #612852) is a syndrome that presents in early infancy with a diffuse pustular skin rash, sterile osteomyelitis, and periostitis with articular pain in the setting of markedly elevated inflammatory markers but no fever. This rare, autosomal recessive condition is due to pathogenic variants in <em>IL1RN</em>, the gene encoding the IL-1RA. Treatment with recombinant IL-1RA, <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a>, results in marked improvement. DIRA is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders", section on 'Deficiency of the IL-1-receptor antagonist (DIRA)'</a>.)</p><p class="headingAnchor" id="H1044170008"><span class="h2">Deficiency of the IL-36 receptor antagonist (DITRA)</span><span class="headingEndMark"> — </span>DITRA (MIM #614204), an IL-1 family member, manifests as diffuse pustular psoriasis [<a href="#rid52">52</a>]. Generalized pustular psoriasis is covered in greater detail separately. (See  <a class="medical medical_review" href="/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Generalized pustular psoriasis'</a>.)</p><p class="headingAnchor" id="H4015862663"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>As with other autoinflammatory diseases, the diagnosis of an inflammasomopathy is considered in patients who present with inflammatory episodes that recur or persist over months or years in the absence of another cause. Unusual infections, systemic juvenile idiopathic arthritis (sJIA; or adult-onset Still's disease [AOSD] in older patients), chronic autoimmune conditions such as inflammatory bowel disease (IBD), and malignancy are first excluded. The evaluation then proceeds with an attempt to identify a clinical pattern consistent with one of the major autoinflammatory disorders. Clinical criteria, in the absence of genetic testing, have been developed for the diagnosis and classification of cryopyrin-associated periodic syndromes (CAPS) and familial Mediterranean fever (FMF) (<a class="graphic graphic_table graphicRef101819" href="/d/graphic/101819.html" rel="external">table 2</a>) [<a href="#rid53">53</a>]. However, genetic testing remains the mainstay of diagnosis for the inflammasomopathies, either targeted to a single gene or more commonly to a panel of autoinflammation-associated diseases. Classification criteria incorporate the results of such genetic testing, considering both unambiguously pathogenic mutations and variants of indeterminate significance, although these newer criteria are intended to be classification criteria rather than diagnostic criteria (<a class="graphic graphic_table graphicRef130006" href="/d/graphic/130006.html" rel="external">table 3</a>)<em> </em>[<a href="#rid54">54</a>]. Pending the results of genetic testing, IL-1 blockade (typically with <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a>) may be used for treatment. IL-18-blocking agents are under development but are unavailable for routine clinical use. (See <a class="local">'Treatment'</a> below.)</p><p>For diseases that present with fever, the most useful discriminators are the duration and periodicity of febrile episodes; ethnicity (eg, Mediterranean descent in FMF); family history of a similar syndrome, which suggests a heritable disorder (although recessive or de novo mutations will often lack such a history); and presence of associated clinical features.</p><p>Diagnosis is important because of potential implications for therapy, monitoring for the development of secondary (amyloid A [AA]) amyloidosis, and the need for genetic counseling. Despite advances in diagnostic testing, many patients still defy diagnostic classification [<a href="#rid55">55-57</a>]. In such cases, reconsideration of the full differential diagnosis is essential. If an autoinflammatory disease still appears likely, empiric therapy patterned on that employed in other clinically similar autoinflammatory diseases is often warranted, including <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> and/or <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> (recombinant IL-1 receptor antagonist [IL-1RA]) [<a href="#rid58">58</a>]. Referral to a center with appropriate expertise to perform exome/genome sequencing, including evaluation for mosaicism (presence of a mutant gene in some cells but not others) (see  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview", section on 'Mosaicism'</a>), or other targeted investigations should be considered and may lead to a definitive diagnosis. (See  <a class="medical medical_review" href="/d/html/116805.html" rel="external">"Genetic testing in patients with a suspected primary immunodeficiency or autoinflammatory syndrome"</a> and  <a class="medical medical_review" href="/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications"</a>.)</p><p class="headingAnchor" id="H258721431"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis includes unusual infections such as relapsing fever, malignancy and premalignant states (Schnitzler syndrome), cyclic neutropenia, inflammatory bowel disease (IBD), and systemic juvenile idiopathic arthritis (sJIA)/adult-onset Still's disease (AOSD). (See  <a class="medical medical_review" href="/d/html/5996.html" rel="external">"Fever of unknown origin in children: Etiology"</a> and  <a class="medical medical_review" href="/d/html/5993.html" rel="external">"Fever of unknown origin in children: Evaluation"</a> and  <a class="medical medical_review" href="/d/html/2737.html" rel="external">"Fever of unknown origin in adults: Etiologies"</a> and  <a class="medical medical_review" href="/d/html/2736.html" rel="external">"Fever of unknown origin in adults: Evaluation and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsing fever – </strong>Relapsing fever is similar in name to periodic fever syndromes. However, relapsing fever is an arthropod-borne infectious disease caused by spirochetes of the <em>Borrelia</em> genus, not an autoinflammatory disease. It is also characterized by recurrent episodes of fever. (See  <a class="medical medical_review" href="/d/html/7897.html" rel="external">"Clinical features, diagnosis, and management of relapsing fever"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclic neutropenia </strong>– Other than periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA), fever in autoinflammatory disorders is episodic rather than truly periodic. Thus, the presence of a predictable recurrent fever pattern should trigger consideration of cyclic neutropenia, which may be of childhood or adult onset. (See  <a class="medical medical_review" href="/d/html/8370.html" rel="external">"Cyclic neutropenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schnitzler syndrome </strong>– Schnitzler syndrome is an acquired autoinflammatory syndrome that presents with chronic urticaria associated with monoclonal immunoglobulin M (IgM) gammopathy (most often IgM kappa). Additional features may include bone pain, skeletal hyperostosis, arthralgias, lymphadenopathy, and intermittent fevers. Patients are at increased risk of hematologic malignancies. There is no specific test for Schnitzler syndrome, and clinicians must maintain a high index of suspicion in patients with chronic urticaria and a monoclonal IgM gammopathy. Most patients respond well to inhibition of the IL-1 pathway. Schnitzler syndrome is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/8218.html" rel="external">"Urticarial vasculitis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic juvenile idiopathic arthritis/adult-onset Still's disease</strong> – A further diagnostic consideration is the febrile-onset arthritis known in childhood as sJIA and in adults as AOSD. Patients with these conditions present with features including high-spiking fevers, rash, serositis, and lymphadenopathy. Arthritis is often evident at onset but may sometimes lag for weeks or months. These clinical features, as well as brisk response to IL-1 antagonism in many patients, suggest that sJIA/AOSD may belong to the family of autoinflammatory diseases, although important differences remain [<a href="#rid59">59</a>]. These diseases are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6413.html" rel="external">"Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5611.html" rel="external">"Clinical manifestations and diagnosis of adult-onset Still's disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory bowel disease (IBD)</strong> – Crohn disease and ulcerative colitis typically present as abdominal pain, diarrhea, weight loss, fatigue, and elevated acute-phase reactants. Untreated disease is typically chronic, although intermittent exacerbations may mimic recurrent conditions. Particularly in Crohn disease, common signs and symptoms may be absent, and extraintestinal inflammation may be present in joints, bones, muscles, and even blood vessels. IBD is considerably more prevalent than inflammasomopathies. A careful personal and family history, physical exam, laboratory tests, and imaging studies should help identify IBD in patients with an undiagnosed inflammatory condition. (See  <a class="medical medical_review" href="/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children"</a> and  <a class="medical medical_review" href="/d/html/5865.html" rel="external">"Clinical manifestations and complications of inflammatory bowel disease in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/7787.html" rel="external">"Clinical manifestations and diagnosis of arthritis associated with inflammatory bowel disease and other gastrointestinal diseases"</a> and  <a class="medical medical_review" href="/d/html/4064.html" rel="external">"Dermatologic and ocular manifestations of inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/d/html/5893.html" rel="external">"Growth failure and pubertal delay in children with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PFAPA syndrome </strong>– Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome is a relatively common entity compared with the other periodic fever syndromes. The etiology of PFAPA has not been defined, and further investigation may ultimately identify it as autoinflammatory.</p><p></p><p class="bulletIndent1">Briefly, PFAPA is characterized by febrile episodes beginning in early childhood that recur approximately every three to four weeks. These episodes are associated with typical clinical features, and another cause is not identifiable. Episodes are abrupt in onset, last three to six days, and may be accompanied by one or more of the following: pharyngitis (exudative or nonexudative), mild aphthous ulcerations, lymphadenopathy, chills (rigors), fatigue, headache, and mild abdominal pain.</p><p></p><p class="bulletIndent1">Despite its acronym, recurrent fevers are the only prominent clinical finding in many patients. Leukocytosis and elevation of inflammatory markers occur acutely during episodes and return to normal between episodes. Patients are healthy between episodes of fever and grow normally, even if they are anorectic and lose weight during the febrile episodes. Most patients with PFAPA outgrow the febrile episodes with time, and no long-term consequences have been identified. PFAPA syndrome is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5953.html" rel="external">"Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemophagocytic lymphohistiocytosis (HLH)</strong> – Patients with defects in inflammasomopathy-associated genes including <em>NLRC4</em>, <em>NLRP12</em>, and<em> CDC42</em> (as well as related genes not yet unambiguously implicated in autoinflammation: <em>NLRP4</em>, <em>NLRC3</em>, and <em>NLRP13</em>) can present with manifestations of HLH, including fevers and cytopenias [<a href="#rid60">60</a>]. Accordingly, inflammasome-related diseases should be considered in patients with HLH, while other causes of HLH (primary or secondary) should be in the differential diagnosis of the inflammasomopathies. (See  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p></p><p class="headingAnchor" id="H944194875"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Inflammation in the inflammasomopathies is commonly mediated at least in part through IL-1-beta, and so blockade of this cytokine can be markedly effective [<a href="#rid61">61-63</a>]. <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> is highly effective in familial Mediterranean fever (FMF), both for prevention of clinical symptoms and for prevention of AA amyloidosis. IL-1 blockade is effective in colchicine-refractory FMF [<a href="#rid63">63</a>]. Blockade of IL-18 is effective in nucleotide-binding oligomerization domain-like receptor family, caspase recruitment domain-containing (NLRC) 4-mediated autoinflammation, but this agent (tadekinig alpha, a recombinant IL-18 binding protein) is available only in the context of a clinical trial or related compassionate use protocols [<a href="#rid46">46</a>]. Nonsteroidal antiinflammatory drugs (NSAIDs) and glucocorticoids may play important ancillary roles. Bone marrow transplantation may be an option for severe refractory disease [<a href="#rid60">60</a>]. Treatment of the most common inflammasomopathies is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/2574.html" rel="external">"Management of familial Mediterranean fever"</a> and  <a class="medical medical_review" href="/d/html/5955.html" rel="external">"Hyperimmunoglobulin D syndrome: Management"</a> and  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a>.)</p><p class="headingAnchor" id="H3405783043"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/121582.html" rel="external">"Society guideline links: Familial Mediterranean fever"</a>.)</p><p class="headingAnchor" id="H846054705"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – The autoinflammatory diseases constitute a family of disorders characterized by aberrant activation of inflammatory pathways in the absence of antigen-directed autoimmunity. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Autoinflammatory diseases mediated by pathogenic variants affecting the inflammasome are called the inflammasomopathies. The inflammasome is an intracellular protein complex responsible for proteolytic activation of interleukin (IL) 1-beta, IL-18, and the pore-forming protein gasdermin D (<a class="graphic graphic_figure graphicRef128994" href="/d/graphic/128994.html" rel="external">figure 1</a>). There are at least six canonical inflammasomes, defined by the scaffold protein responsible for their assembly: pyrin, cryopyrin (nucleotide-binding oligomerization domain-like receptor family, caspase recruitment domain-containing [NLRC] 3), NLRC4, nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing (NLRP) 1, NLRP12, and absent in melanoma (AIM) 2. Pathogenic variants in each of these proteins, with the exception of AIM2, have been shown to cause human autoinflammatory disease. (See <a class="local">'Overview of the inflammasome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of inflammasomopathies</strong> – The most well-known inflammasomopathies are familial Mediterranean fever (FMF) due to mutations in pyrin and the cryopyrin-associated periodic syndromes (CAPS; familial cold autoinflammatory syndrome [FCAS], Muckle-Wells syndrome [MWS], and neonatal-onset multisystem inflammatory disease [NOMID]) caused by mutations in <em>NLRP3</em>. (See <a class="local">'The pyrin inflammasome'</a> above and <a class="local">'The cryopyrin inflammasome'</a> above.)</p><p></p><p class="bulletIndent1">Other diseases related to excess activity of IL-1-family cytokines include deficiency of the IL-1RA and of the IL-36 receptor antagonist (DIRA and DITRA). (See <a class="local">'Diseases related to other IL-1 family proteins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Inflammasome-mediated autoinflammatory diseases should be suspected when a patient presents with recurrent episodes of inflammation over months or years unexplained by another cause. Most patients develop their first disease manifestations in childhood. Features can include fevers, urticarial rashes, meningitis, bone overgrowth, and enterocolitis. Disorders of the NLRP1 inflammasome present with disease localized to skin. Genetic testing is typically employed to confirm a clinically suspected entity. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis includes unusual infections such as relapsing fever, malignancy, cyclic neutropenia, inflammatory bowel disease (IBD), systemic juvenile idiopathic arthritis (sJIA)/adult-onset Still's disease (AOSD), and hemophagocytic lymphohistiocytosis (HLH). Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a common syndrome of recurrent unexplained fever in children. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment of the inflammasomopathies varies with etiology and may include <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, IL-1 blockade, nonsteroidal antiinflammatory drugs (NSAIDs), and glucocorticoids. IL-18 blockade is experimental. (See <a class="local">'Treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10:417.</a></li><li><a class="nounderline abstract_t">Mathur A, Hayward JA, Man SM. Molecular mechanisms of inflammasome signaling. J Leukoc Biol 2018; 103:233.</a></li><li><a class="nounderline abstract_t">Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov 2020; 6:36.</a></li><li><a class="nounderline abstract_t">Zhu Q, Kanneganti TD. Cutting Edge: Distinct Regulatory Mechanisms Control Proinflammatory Cytokines IL-18 and IL-1β. J Immunol 2017; 198:4210.</a></li><li><a class="nounderline abstract_t">Evavold CL, Ruan J, Tan Y, et al. The Pore-Forming Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages. Immunity 2018; 48:35.</a></li><li><a class="nounderline abstract_t">Xia S, Zhang Z, Magupalli VG, et al. Gasdermin D pore structure reveals preferential release of mature interleukin-1. Nature 2021; 593:607.</a></li><li><a class="nounderline abstract_t">Gross O, Yazdi AS, Thomas CJ, et al. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36:388.</a></li><li><a class="nounderline abstract_t">Jorgensen I, Zhang Y, Krantz BA, Miao EA. Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis. J Exp Med 2016; 213:2113.</a></li><li><a class="nounderline abstract_t">Shi CS, Shenderov K, Huang NN, et al. Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 2012; 13:255.</a></li><li><a class="nounderline abstract_t">Baroja-Mazo A, Martín-Sánchez F, Gomez AI, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol 2014; 15:738.</a></li><li><a class="nounderline abstract_t">Franklin BS, Bossaller L, De Nardo D, et al. The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation. Nat Immunol 2014; 15:727.</a></li><li><a class="nounderline abstract_t">Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997; 90:797.</a></li><li><a class="nounderline abstract_t">French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17:25.</a></li><li><a class="nounderline abstract_t">Chung LK, Park YH, Zheng Y, et al. The Yersinia Virulence Factor YopM Hijacks Host Kinases to Inhibit Type III Effector-Triggered Activation of the Pyrin Inflammasome. Cell Host Microbe 2016; 20:296.</a></li><li><a class="nounderline abstract_t">Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I. The Pyrin Inflammasome in Health and Disease. Front Immunol 2019; 10:1745.</a></li><li><a class="nounderline abstract_t">Gao W, Yang J, Liu W, et al. Site-specific phosphorylation and microtubule dynamics control Pyrin inflammasome activation. Proc Natl Acad Sci U S A 2016; 113:E4857.</a></li><li><a class="nounderline abstract_t">Chae JJ, Cho YH, Lee GS, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 2011; 34:755.</a></li><li><a class="nounderline abstract_t">Masters SL, Lagou V, Jéru I, et al. Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. Sci Transl Med 2016; 8:332ra45.</a></li><li><a class="nounderline abstract_t">Moghaddas F, Llamas R, De Nardo D, et al. A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever. Ann Rheum Dis 2017; 76:2085.</a></li><li><a class="nounderline abstract_t">Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 2016; 17:914.</a></li><li><a class="nounderline abstract_t">Akula MK, Shi M, Jiang Z, et al. Control of the innate immune response by the mevalonate pathway. Nat Immunol 2016; 17:922.</a></li><li><a class="nounderline abstract_t">Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002; 11:961.</a></li><li><a class="nounderline abstract_t">Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003; 100:13501.</a></li><li><a class="nounderline abstract_t">Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 2005; 44:406.</a></li><li><a class="nounderline abstract_t">Geusau A, Mothes-Luksch N, Nahavandi H, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol 2013; 149:209.</a></li><li><a class="nounderline abstract_t">Smith EJ, Allantaz F, Bennett L, et al. Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review. Curr Genomics 2010; 11:519.</a></li><li><a class="nounderline abstract_t">Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 2013; 149:762.</a></li><li><a class="nounderline abstract_t">Demidowich AP, Freeman AF, Kuhns DB, et al. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum 2012; 64:2022.</a></li><li><a class="nounderline abstract_t">Mistry P, Carmona-Rivera C, Ombrello AK, et al. Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome. Ann Rheum Dis 2018; 77:1825.</a></li><li><a class="nounderline abstract_t">Holzinger D, Fassl SK, de Jager W, et al. Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated inflammatory diseases. J Allergy Clin Immunol 2015; 136:1337.</a></li><li><a class="nounderline abstract_t">Fessatou S, Fagerhol MK, Roth J, et al. Severe anemia and neutropenia associated with hyperzincemia and hypercalprotectinemia. J Pediatr Hematol Oncol 2005; 27:477.</a></li><li><a class="nounderline abstract_t">Standing AS, Malinova D, Hong Y, et al. Autoinflammatory periodic fever, immunodeficiency, and thrombocytopenia (PFIT) caused by mutation in actin-regulatory gene WDR1. J Exp Med 2017; 214:59.</a></li><li><a class="nounderline abstract_t">Kile BT, Panopoulos AD, Stirzaker RA, et al. Mutations in the cofilin partner Aip1/Wdr1 cause autoinflammatory disease and macrothrombocytopenia. Blood 2007; 110:2371.</a></li><li><a class="nounderline abstract_t">Kuhns DB, Fink DL, Choi U, et al. Cytoskeletal abnormalities and neutrophil dysfunction in WDR1 deficiency. Blood 2016; 128:2135.</a></li><li><a class="nounderline abstract_t">Kim ML, Chae JJ, Park YH, et al. Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β. J Exp Med 2015; 212:927.</a></li><li><a class="nounderline abstract_t">Lam MT, Coppola S, Krumbach OHF, et al. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J Exp Med 2019; 216:2778.</a></li><li><a class="nounderline abstract_t">Nishitani-Isa M, Mukai K, Honda Y, et al. Trapping of CDC42 C-terminal variants in the Golgi drives pyrin inflammasome hyperactivation. J Exp Med 2022; 219.</a></li><li><a class="nounderline abstract_t">Bekhouche B, Tourville A, Ravichandran Y, et al. A toxic palmitoylation of Cdc42 enhances NF-κB signaling and drives a severe autoinflammatory syndrome. J Allergy Clin Immunol 2020; 146:1201.</a></li><li><a class="nounderline abstract_t">Ferguson PJ, Chen S, Tayeh MK, et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet 2005; 42:551.</a></li><li><a class="nounderline abstract_t">Lordén G, Sanjuán-García I, de Pablo N, et al. Lipin-2 regulates NLRP3 inflammasome by affecting P2X7 receptor activation. J Exp Med 2017; 214:511.</a></li><li><a class="nounderline abstract_t">Majeed HA, Kalaawi M, Mohanty D, et al. Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. J Pediatr 1989; 115:730.</a></li><li><a class="nounderline abstract_t">Herlin T, Fiirgaard B, Bjerre M, et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis 2013; 72:410.</a></li><li><a class="nounderline abstract_t">Romberg N, Al Moussawi K, Nelson-Williams C, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 2014; 46:1135.</a></li><li><a class="nounderline abstract_t">Canna SW, de Jesus AA, Gouni S, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 2014; 46:1140.</a></li><li><a class="nounderline abstract_t">Weiss ES, Girard-Guyonvarc'h C, Holzinger D, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood 2018; 131:1442.</a></li><li><a class="nounderline abstract_t">Canna SW, Girard C, Malle L, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol 2017; 139:1698.</a></li><li><a class="nounderline abstract_t">Harapas CR, Steiner A, Davidson S, Masters SL. An Update on Autoinflammatory Diseases: Inflammasomopathies. Curr Rheumatol Rep 2018; 20:40.</a></li><li><a class="nounderline abstract_t">Grandemange S, Sanchez E, Louis-Plence P, et al. A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis). Ann Rheum Dis 2017; 76:1191.</a></li><li><a class="nounderline abstract_t">Jéru I, Duquesnoy P, Fernandes-Alnemri T, et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci U S A 2008; 105:1614.</a></li><li><a class="nounderline abstract_t">Wang HF. NLRP12-associated systemic autoinflammatory diseases in children. Pediatr Rheumatol Online J 2022; 20:9.</a></li><li><a class="nounderline abstract_t">Allen IC, Wilson JE, Schneider M, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. Immunity 2012; 36:742.</a></li><li><a class="nounderline abstract_t">Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365:620.</a></li><li><a class="nounderline abstract_t">Federici S, Sormani MP, Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 2015; 74:799.</a></li><li><a class="nounderline abstract_t">Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 2019; 78:1025.</a></li><li><a class="nounderline abstract_t">Simon A, van der Meer JW, Vesely R, et al. Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology (Oxford) 2006; 45:269.</a></li><li><a class="nounderline abstract_t">Omoyinmi E, Standing A, Keylock A, et al. Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis. PLoS One 2017; 12:e0181874.</a></li><li><a class="nounderline abstract_t">Papa R, Rusmini M, Volpi S, et al. Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers. Rheumatology (Oxford) 2020; 59:458.</a></li><li><a class="nounderline abstract_t">Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight 2016; 1:e86336.</a></li><li><a class="nounderline abstract_t">Nigrovic PA. Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A 2015; 112:15785.</a></li><li><a class="nounderline abstract_t">Chinn IK, Eckstein OS, Peckham-Gregory EC, et al. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood 2018; 132:89.</a></li><li><a class="nounderline abstract_t">Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355:581.</a></li><li><a class="nounderline abstract_t">Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 2012; 64:2375.</a></li><li><a class="nounderline abstract_t">De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med 2018; 378:1908.</a></li></ol></div><div id="topicVersionRevision">Topic 122506 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12191486" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28855232" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Molecular mechanisms of inflammasome signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32550001" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Inflammasome activation and regulation: toward a better understanding of complex mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28468974" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cutting Edge: Distinct Regulatory Mechanisms Control Proinflammatory Cytokines IL-18 and IL-1β.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29195811" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Pore-Forming Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33883744" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Gasdermin D pore structure reveals preferential release of mature interleukin-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22444631" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Inflammasome activators induce interleukin-1αsecretion via distinct pathways with differential requirement for the protease function of caspase-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27573815" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22286270" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Activation of autophagy by inflammatory signals limits IL-1βproduction by targeting ubiquitinated inflammasomes for destruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24952504" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24952505" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9288758" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9288094" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A candidate gene for familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27569559" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Yersinia Virulence Factor YopM Hijacks Host Kinases to Inhibit Type III Effector-Triggered Activation of the Pyrin Inflammasome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31456795" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Pyrin Inflammasome in Health and Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27482109" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Site-specific phosphorylation and microtubule dynamics control Pyrin inflammasome activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21600797" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1βactivation and severe autoinflammation in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27030597" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28835462" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27270401" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27270400" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Control of the innate immune response by the mevalonate pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11971877" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14595024" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15637033" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Anakinra for flares of pyogenic arthritis in PAPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23426477" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21532836" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23571383" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161697" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30131320" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26025129" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16189440" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Severe anemia and neutropenia associated with hyperzincemia and hypercalprotectinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27994071" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Autoinflammatory periodic fever, immunodeficiency, and thrombocytopenia (PFIT) caused by mutation in actin-regulatory gene WDR1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17515402" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mutations in the cofilin partner Aip1/Wdr1 cause autoinflammatory disease and macrothrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27557945" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cytoskeletal abnormalities and neutrophil dysfunction in WDR1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26008898" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31601675" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35482294" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Trapping of CDC42 C-terminal variants in the Golgi drives pyrin inflammasome hyperactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283203" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A toxic palmitoylation of Cdc42 enhances NF-κB signaling and drives a severe autoinflammatory syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994876" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28031477" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lipin-2 regulates NLRP3 inflammasome by affecting P2X7 receptor activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2809904" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23087183" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy of anti-IL-1 treatment in Majeed syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25217960" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25217959" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29326099" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27876626" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29846819" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : An Update on Autoinflammatory Diseases: Inflammasomopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27965258" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230725" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mutations in NALP12 cause hereditary periodic fever syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35123508" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : NLRP12-associated systemic autoinflammatory diseases in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22503542" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21848462" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25637003" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31018962" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Classification criteria for autoinflammatory recurrent fevers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234278" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28750028" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31410474" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27699261" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26677874" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29632024" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899778" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22294344" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29768139" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
